Stock listing

KRX:068270 Celltrion, Inc. (셀트리온) 주가

Follow Celltrion, Inc. into a list and get an email when it puts out news.

Share price · KRX:068270

₩194,000 KRW +11,900 (+6.5%)

Close on Oct 16, 2026

Since Jul 6, 2026 +10.3% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
₩183,800 – ₩195,500 KRWOct 16, 2026
Volume
1.10M sharesOct 16, 2026
Market value
₩44.24T KRWAt the close on Oct 16, 2026 · price × 228.0M shares outstanding
Celltrion, Inc. logo
Ticker
KRX:068270
Asset type
Stock
Exchange
KRX
Currency
KRW

What changed lately

Latest news

Celltrion Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability

Jul 26, 2026

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

Apr 21, 2026

Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation

Mar 16, 2026

Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Mar 13, 2026

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026

Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

Dec 1, 2025

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

Nov 26, 2025

Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases

Nov 3, 2025

U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)

Oct 30, 2025

All Celltrion, Inc. news

Celltrion, Inc. on 6ix

News releases
10 in the last 12 months · 27 in all · newest Jul 27, 2026 · oldest 2021

Log in to ask 6ix AI your own questions about Celltrion, Inc.